| Date | Title | | | 11/14/08 | Cephalon Added to S&P 500 Today| FRAZER, Pa., Nov. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq:
CEPH) today announced that Standard and Poor's will add Cephalon to the S&P
500 Index after the close of trading on Friday, November 14. Cephalon has
been listed in the S&P MidCap 400 Index.
"We are honored to be recognized among the foremost companies in the
United States," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "This
distinction is a result of the talented and dedicated employees who are
committ... |
|  | | 11/03/08 | Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma| TREANDA Receives Second Indication this Year; Data Demonstrate High,
Durable Response Rates for Patients with indolent NHL Who Have Progressed
Following a Rituximab-Containing Regimen
FRAZER, Pa., Nov. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq:
CEPH) today announced that the U.S. Food and Drug Administration (FDA) has
approved TREANDA(R) (bendamustine hydrochloride) for Injection for the
treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that
has pro... |
| | | 10/31/08 | Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma| TREANDA Receives Second Indication this Year;
Data Demonstrate High, Durable Response Rates for Patients with indolent NHL
Who Have Progressed Following a Rituximab-Containing Regimen
FRAZER, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc.,
(Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration
(FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for
the treatment of patients with indolent B-cell non-Hodgkin's lymph... |
| | | 10/30/08 | Cephalon, Inc. to Webcast Analyst Day| FRAZER, Pa., Oct 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cephalon, Inc.
(Nasdaq: CEPH) today announced that its Analyst Day in New York City, to be
held on November 5, 2008, will be webcast live on the investor relations
section of its website at http://www.cephalon.com.
Cephalon's senior management will review the company's business strategy,
marketing plan and research and development initiatives. The presentations
will be delivered on Wednesday, November 5, 2008 begin... |
| |
|
Print Page | 
Email Page | 
RSS Feeds | 
Financial Tear Sheet